デフォルト表紙
市場調査レポート
商品コード
1480620

肺/呼吸器ドラッグデリバリーの世界市場

Pulmonary / Respiratory Drug Delivery

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 194 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.74円
肺/呼吸器ドラッグデリバリーの世界市場
出版日: 2024年05月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

肺/呼吸器ドラッグデリバリーの世界市場は2030年までに777億米ドルに達する見込み

2023年に560億米ドルと推定される肺/呼吸器ドラッグデリバリーの世界市場は、分析期間2023年から2030年にかけてCAGR 4.8%で成長し、2030年には777億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである定量噴霧式吸入器は、CAGR 4.3%を記録し、分析期間終了時には327億米ドルに達すると予測されます。乾燥粉末吸入器セグメントの今後7年間のCAGRは5.5%と推定されます。

米国市場は168億米ドルと推定、中国はCAGR4.5%で成長予測

米国の肺/呼吸器ドラッグデリバリー市場は、2023年には168億米ドルになると推定されます。世界第2位の経済大国である中国は、2030年までに136億米ドルの市場規模に達すると予測され、分析期間2023年から2030年までのCAGRは4.5%です。その他の注目すべき地理的市場としては、日本とカナダがあり、それぞれ2023年から2030年にかけて4%と4%の成長が予測されています。欧州では、ドイツがCAGR約3.6%で成長すると予測されています。

2024年の魅力的な新レポート機能のご紹介

インフルエンサーのエンゲージメント統計へのフルアクセス

デジタルアーカイブと「MarketGlass」調査プラットフォームへの無料アクセス。当社独自のMarketGlassプラットフォームは、世界中の専門家の創造性と市場知識を統合的かつ協調的に解き放つことができます。当社の最先端のツールは、市場参入企業のプライバシーとアイデンティティを保護しながら、世界クラスの市場展望をもたらします。レポート内の数字、統計、市場に関する説明は、この分野の専門家や影響力のある人々によって共有された、完全にキュレートされた洞察に基づいています。

リアルタイムのデータシミュレーター・ツールや特注のレポート作成機能を備えたインタラクティブなアンケートに参加できます。

企業間のスマートな意見交換のためのピアコラボレーティブ・インタラクティブプラットフォームへのフルクライアントアクセス

1年間の無料レポート更新

主要プレーヤーの世界市場シェアを含む競合カバレッジ

複数の地域にまたがるプレーヤーの市場プレゼンス分析(好調/活発/ニッチ/マイナー)

専門家/インフルエンサーのインタビュー、ポッドキャスト、プレス発表、イベント基調講演のYouTubeビデオへのアクセス

2024年の世界経済に期待すること

金融引き締めとそれに伴う金利上昇によって引き起こされる地政学的、経済的不安定性が、2024年の激動の情勢を作り出すと思われます。中東での敵対行為や、ますます頻発する気候災害など、いくつかの要因が回復への道筋に圧力をかけ続けると思われます。リスクの一方で、ディスインフレの兆候が強まり、頑迷なインフレに対する不安が緩和され、サプライチェーンが正常化し、エネルギーコストの変動にもかかわらず物価が緩やかになるなど、いくつかのプラス材料も具体化しつつあります。インドや米国をはじめとするG21諸国の選挙は、資本の流れや投資戦略に影響を与える可能性があります。インドが世界な投資先として注目される一方で、米国を拠点とするハイテク企業は、才能と資本のダイナミックなエコシステムに後押しされ、引き続き優位を保つと思われます。シリコンバレーをはじめとするハイテク機会は、国内経済が減速しているとはいえ底堅く、規制環境も整備されていることから、高成長の可能性を求める投資家にとって引き続き魅力的です。欧州は金融引き締め政策と景気後退リスクとの戦いが続くが、英国は見通しが最も厳しく、2024年の景気後退リスクが最も高いです。中国は、政府支出と個人消費の改善に支えられた成長が期待されるもの、引き続きワイルドカードとなります。不安定な環境は、投資家にも企業にもチャンスと課題の両方をもたらすと思われます。成長への触媒としてボラティリティを受け入れるとともに、投資判断における敏捷性と戦略的先見性が生き残るために重要であることに変わりはないです。

調査対象企業の例(全42件)

  • AireHealth, LLC
  • Allergenix
  • Channel Products
  • Chemring Group PLC
  • Epalex Corp.
  • Genetic SpA
  • Micot
  • Omron Healthcare India
  • Pneuma Respiratory
  • Rotech Healthcare, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP14284

Global Pulmonary / Respiratory Drug Delivery Market to Reach $77.7 Billion by 2030

The global market for Pulmonary / Respiratory Drug Delivery estimated at US$56 Billion in the year 2023, is expected to reach US$77.7 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2023-2030. Metered Dose Inhalers, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$32.7 Billion by the end of the analysis period. Growth in the Dry Powder Inhalers segment is estimated at 5.5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $16.8 Billion, While China is Forecast to Grow at 4.5% CAGR

The Pulmonary / Respiratory Drug Delivery market in the U.S. is estimated at US$16.8 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$13.6 Billion by the year 2030 trailing a CAGR of 4.5% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4% and 4% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 42 Featured) -

  • AireHealth, LLC
  • Allergenix
  • Channel Products
  • Chemring Group PLC
  • Epalex Corp.
  • Genetic SpA
  • Micot
  • Omron Healthcare India
  • Pneuma Respiratory
  • Rotech Healthcare, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Pulmonary/ Respiratory Drug Delivery - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Asthma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Asthma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Cystic Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Cystic Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Pulmonary / Respiratory Drug Delivery Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Pulmonary / Respiratory Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Metered Dose Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Metered Dose Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Metered Dose Inhalers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Dry Powder Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Dry Powder Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Dry Powder Inhalers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Nebulizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Nebulizers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Nebulizers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Chronic Obstructive Pulmonary Disease (COPD) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2024 & 2030
  • JAPAN
    • Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2024 & 2030
  • CHINA
    • Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2024 & 2030
  • EUROPE
    • Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Pulmonary / Respiratory Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2024 & 2030
  • FRANCE
    • Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2024 & 2030
  • GERMANY
    • Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Pulmonary / Respiratory Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Pulmonary / Respiratory Drug Delivery by Application - Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Application - Percentage Breakdown of Value Sales for Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Pulmonary / Respiratory Drug Delivery by Product - Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of World 16-Year Perspective for Pulmonary / Respiratory Drug Delivery by Product - Percentage Breakdown of Value Sales for Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers for the Years 2014, 2024 & 2030

IV. COMPETITION